Advanced glycation end products (AGEs) activate mast cells

British Journal of Pharmacology

Volumn 161, Issue 2, 2010, Pages 442-455

  Sick, E ^a,b   Brehin, S ^a,b   Andre P ^a,b   Coupin, G ^a,b   Landry, Y ^a,b   Takeda, K ^a,b   Gies, J P ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Faculté de Pharmacie   (France)

Author keywords

AGEs; exocytosis; inflammation; mast cells; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BINDING PROTEIN; CAFFEINE; CALCIUM; CALCIUM ION; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; HISTAMINE; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; MONOCLONAL ANTIBODY; PERTUSSIS TOXIN; RAGE PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL ACTIVATION; CELL STIMULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME SYNTHESIS; EXOCYTOSIS; HISTAMINE RELEASE; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; MOLECULAR INTERACTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CALCIUM; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXOCYTOSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HISTAMINE RELEASE; IMMUNOHISTOCHEMISTRY; MALE; MAST CELLS; MICROSCOPY, FLUORESCENCE; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 77956038452     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00905.x     Document Type: Article

References (77)

1. André P, Metzger C, Petey S, Muller D, Vidon DJ (2005). Chemiluminescence of enterococci isolates from freshwater. FEMS Microbiol Lett 245 : 123 129.
2. i3. Science 262 : 1569 1572.
3. Baynes JW (2001). The role of AGEs in aging: causation or correlation. Exp Gerontol 36 : 1527 1532.
4. Bischoff SC (2007). Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol 7 : 93 104.
5. Blank U, Rivera J (2004). The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol 25 : 266 273.
6. Brookes PS, Yoon Y, Robothan JL, Anders MW, Sheu SS (2004). Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol 287 : C817 C833.
7. Brooks AC, Whelan CJ, Purcell WM (1999). Reactive oxygen species generation and histamine release by activated mast cells: modulation by nitric oxide synthase inhibition. Br J Pharmacol 128 : 585 590.
8. Brownlee M (1992). Glycation products and the pathogenesis of diabetes. Diabetes Care 15 : 1835 1843.
9. Bueb JL, Da Silva A, Mousli M, Landry Y (1992). Natural polyamines stimulate G-proteins. Biochem J 282 : 545 550.
10. 45calcium with rat mast cells stimulated by 48/80: effects of inactivation, calcium ad metabolic inhibition. J Physiol (Lond) 330 : 413 427.
11. Degryse B, Bonaldi T, Scaffidi P, Müller S, Resnati M, Sanvito F et al. (2001). The High Mobility Group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152 : 1197 1206.
12. Dröge W, Schipper M (2007). Oxidative stress and aberrant signalling in aging and cognitive decline. Aging Cell 6 : 361 370.
13. Ehrlich P (1879). Beiträge zur Kenntniss der granulirten Bindegewebszellen und der eosinophilen Leukocythen. Arch Anat Physiol 3 : 166 169.
14. El Khoury J, Thomas CA, Loike JD, Hickman SE, Cao L, Silverstein SC (1994). Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem 269 : 10197 10200.
15. i3 proteins by basic secretagogues induce exocytosis through phospholipase Cβ and arachidonate release through phospholipase Cβ in mast cells. J Immunol 167 : 4805 4813.
16. Ferry X, Brehin S, Kamel R, Landry Y (2002). G protein-dependent activation of mast cells by peptides and basic secretagogues. Peptides 23 : 1507 1515.
17. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CMM, Tsai M (2005). Mast cells as 'tunable' effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23 : 749 786.
18. Galli SJ, Grimbalderson M, Tsai M (2008). Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8 : 478 486.
19. Gianonne G, Ronde P, Gaire M, Beaudouin J, Haiech J, Ellenberg J et al. (2004). Calcium rises locally trigger focal adhesion disassembly and enhance residency of focal adhesion kinase at focal adhesions. J Biol Chem 279 : 28715 28723.
20. Gies JP, Landry Y, Mousli M (1993). Receptor-independent activation of mast cells by bradykinin and related peptides. Trends Neurosci 16 : 498 999.
21. Gurish MF, Austen KF (2001). The diverse roles of mast cells. J Exp Med 194 : 1 5.
22. Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM et al. (2004). Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 279 : 50019 50024.
23. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y et al. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 : 889 901.
24. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX et al. (1995). The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem 270 : 25752 25761.
25. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W et al. (2003). Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 419 : 80 88.
26. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H (2005). Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64 : 92 100.
27. Kassel O, Amrani Y, Landry Y, Bronner C (1995). Mast cell activation involves membrane potential- and thapsigargin- sensitive intracellular calcium pools. Fund Clin Pharmacol 9 : 531 539.
28. Kuniyasu H, Chihara Y, Kondo H (2003). Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 104 : 722 727.
29. Lander HL, Tauras JM, Ogiste JS, Moss RA, Schmidt AM (1997). Activation of the receptor for advanced glycation endproducts triggers a MAP kinase pathway regulated by oxidant stress. J Biol Chem 272 : 17810 17814.
30. Landry Y, Niederhoffer N, Sick E, Gies JP (2006). Heptahelical and other G-protein-coupled receptors (GPCRs) signalling. Curr Med Chem 13 : 51 63.
31. Lappas M, Permezel M, Rice GE (2007). Advanced glycation endproducts mediate pro-inflammatory actions in human gestational tissues via nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Endocrinol 193 : 269 277.
32. Leal-Berumen I, Conlon P, Marshall JS (1994). IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. J Immunol 152 : 5468 5476.
33. Li SY, Du M, Dolence EK, Fang CX, Mayer GE, Ceylan-Isik AF et al. (2005). Aging induces cardiac diastolic dysfunction, oxidative stress, accumulation of advanced glycation endproducts and protein modification. Aging Cell 4 : 57 64.
34. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A et al. (1996). Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 93 : 11047 11052.
35. Li J, Schmidt AM (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation endproducts. J Biol Chem 272 : 16498 16506.
36. Liu R, Mori S, Wake H, Zhang J, Liu K, Izushi Y et al. (2009). Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding. Acta Med Okayama 63 : 203 211.
37. Lynch JW, Lemos VS, Bucher B, Stoclet JC, Takeda K (1994). A Pertussis toxin-sensitive calcium influx mediated by neuropeptide Y2 receptors in a human neuroblastoma cell line. J Biol Chem 269 : 8226 8233.
38. Marshall JS (2004). Mast-cell responses to pathogens. Nat Rev Immunol 4 : 787 799.
39. 2. Release J Biochem 122 : 498 505.
40. Mercer N, Ahmed H, McCarthy AD, Etcheverry SB, Vasta GR, Cortizo AM (2004). AGE-R3/galectin-3 expression in osteoblast-like cells: regulation by AGEs. Mol Cell Biochem 266 : 17 24.
41. Metcalfe DD, Baram D, Mekori YA (1997). Mast cells. Physiol Rev 77 : 1033 1079.
42. Miller LA, Cochrane DE, Carraway RE, Feldberg RS (1995). Blockade of mast cell histamine secretion in response to neurotensin by SR 48692, a nonpeptide antagonist of the neurotensin brain receptor. Br J Pharmacol 114 : 1466 1470.
43. Mohr FC, Fewtrell C (1990). The effect of mitochondrial inhibitors on calcium homeostasis in tumor mast cells. Am J Physiol 258 : C217 C226.
44. Mousli M, Bronner C, Bueb JL, Tschirhart E, Gies JP, Landry Y (1989). Activation of rat peritoneal mast cells by substance P and mastoparan. J Pharmacol Exp Ther 250 : 329 335.
45. Mousli M, Hugli TE, Landry Y, Bronner C (1992). A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J Immunol 148 : 2456 2461.
46. Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H et al. (2006). RAGE control of diabetic nephropathy in a mouse model. Diabetes 55 : 2510 2522.
47. Nah SS, Choi IY, Yoo B, Kim YG, Moon HB, Lee CK (2007). Advanced glycation end products increases matrix metalloproteinase-1, -3, and -13, and TNF-α in human osteoarthritic chondrocytes. FEBS Lett 581 : 1928 1932.
48. 2+-mobilizing receptor-mediated biosignaling system. J Biol Chem 260 : 3584 3593.
49. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267 : 14998 15004.
50. Nishikawa T, Du Edelstein DXL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA et al. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 : 787 790.
51. Niu XF, Ibbotson G, Kubes P (1996). A balance between nitric oxide and oxidants regulates mast cell-dependent neutrophil-endothelial cell interactions. Circ Res 79 : 992 999.
52. Ohgami N, Nagai R, Ikemoto M, Arai H, Miyazaki A, Hakamata H et al. (2002). CD36 serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complic 16 : 56 59.
53. Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM et al. (2008). Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 28 : 3521 3530.
54. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 : 1025 1031.
55. Ramasamy R, Vannucci SJ, Yan SSD, Herold K, Yan SF, Schmidt AM (2005). Arguing for the motion: yes, RAGE is a receptor for advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration and inflammation. Glycobiology 15 : 1111 1115.
56. Rüster C, Bondeva T, Franke S, Förster M, Wolf G (2008). Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 23 : 2179 2191.
57. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J et al. (1992). Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267 : 14987 14997.
58. Schmidt AM, Yan SD, Yan SF, Stern DM (2001). The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108 : 16R 28R.
59. Sick E, Niederhoffer N, Takeda K, Landry Y, Gies JP (2009). Activation of CD47 receptors causes histamine secretion from mast cells. Cell Mol Life Sci 66 : 1271 1282.
60. Singh R, Barden A, Mori T, Beilin L (2001). Advanced glycation end-products: a review. Diabetologia 44 : 129 146.
61. Sorci G, Riuzzi F, Agneletti AL, Marchetti C, Donato R (2003). S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner. Mol Cell Biol 23 : 4870 4881.
62. Suzuki Y, Inoue T, Yoshimaru T, Ra C (2008). Galectin-3 but not galectin-1 induces mast cell death by oxidative stress and mitochondrial permeability transition. Biochim Biophys Acta 1783 : 924 934.
63. Swindle EJ, Metcalfe DD, Coleman JW (2004). Rodent and human mast cells produce functionally significant intracellular reactive oxygen species but not nitric oxide. J Biol Chem 279 : 48751 48759.
64. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W et al. (2000). Blockade of RAGE-amphoterin signaling suppresses tumour growth and metastases. Nature 405 : 354 360.
65. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y (2009). Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 46 : 572 580.
66. 2+ influx and histamine secretion independent of cAMP in rat peritoneal mast cells. Gen Pharmacol 28 : 237 243.
67. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D (2007). Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 217 : 65 78.
68. Togashi K, Inada H, Tominaga M (2008). Inhibition of the transient potential cation channel TRPM2 by 2-aminoethoxydiphenyl borate (2-APB). Br J Pharmacol 153 : 1324 1330.
69. Touré F, Zahm JM, Garnotel R, Lambert E, Bonnet N, Schmidt AM et al. (2008). Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix. Biochem J 416 : 255 261.
70. Valencia JV, Weldon SC, Quinn D, Kiers GH, DeGroot J, TeKoppele JM et al. (2004). Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem 324 : 68 78.
71. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT et al. (1995). Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1 : 634 646.
72. Wang Z, Li D, Liang Y, Wang D, Cai N (2002). Activation of astrocytes by advanced glycation end products: cytokines induction and nitric oxide release. Acta Pharmacol Sin 23 : 974 980.
73. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001). Activation of NADPH oxidase by advanced glycation endproducts (AGEs) links oxidant stress to altered gene expression via RAGE. Am J Physiol 280 : E685 E694.
74. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A et al. (1996). RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 : 674 675.
75. Yan SD, Schmidt AM, Anderson G, Zhang J, Brett J, Zou YS et al. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding protein. J Biol Chem 269 : 9889 9897.
76. Yan SF, Ramasamy R, Naka Y, Schmidt AM (2003). Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Re 93 : 1159 1169.
77. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ (2007). High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 81 : 59 66.